Meso Scale Diagnostics

What Meso Scale Diagnostics does

Meso Scale Diagnostics (MSD), founded in 1995 and headquartered in Rockville, Maryland, is a privately-held developer and manufacturer of multiplex biomarker measurement assays and instruments. The company operates a vertically integrated platform centered on its proprietary electrochemiluminescence (ECL) detection technology combined with its MULTI-ARRAY architecture, which enables simultaneous measurement of multiple analytes from a single biological sample without compromising assay sensitivity. Its three proprietary instrument platforms (MESO SECTOR S 600MM, QuickPlex SQ 120MM, and QuickPlex Q 60MM) run five assay families (V-PLEX, U-PLEX, S-PLEX, R-PLEX, T-PLEX) covering thousands of biomarkers across applications including cytokines, neurodegeneration, cardiovascular disease, oncology, and infectious disease. Data analysis is supported by DISCOVERY WORKBENCH and Methodical Mind software, and the platform is anchored by specialized 96- and 384-well immunoassay plates and a complete reagent/buffer consumable portfolio.

The company's customer base spans pharmaceutical and biotechnology companies, academic research institutions, clinical laboratories, government institutions, and contract research organizations across North America, 11 European countries, and Asia (Japan, China). MSD generates revenue through a razor-and-blade model combining upfront instrument sales with recurring consumables (assay kits, plates, reagents, buffers), complemented by a fee-for-services business spanning custom assay development, biomarker screening, S-PLEX high-sensitivity sample testing (including Tau pT217 and pT181 for Alzheimer's research), custom conjugation, and prototype printing. Distribution occurs through direct e-commerce, customer service teams handling phone/fax/email orders, and a global network of regional distributors, supported by wholly-owned operating entities Meso Scale UK Limited, Meso Scale Japan KK., and Meso Scale (Shanghai) Training Co., Ltd.

With over 900 employees worldwide and ISO 9001:2015 and ISO 13485:2016 certifications covering design, development, manufacture, distribution, and service, MSD secured its first FDA-cleared in vitro diagnostic assay in January 2018, marking a regulatory transition from research-use-only products toward regulated clinical diagnostics. The company has invested in high-sensitivity applications through its S-PLEX platform (offering up to 100x ELISA sensitivity for low-abundance neurological biomarkers such as neurofilament L, GFAP, and tau), and demonstrated public-health responsiveness through COVID-19 antibody test launches supporting vaccine clinical trials and SARS-CoV-2 variant surveillance in 2020-2021.

Name

Meso Scale Diagnostics

Legal name

Meso Scale Diagnostics, LLC.

Website

https://mesoscale.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

251–500 employees

Short description

Meso Scale Diagnostics is a Rockville, Maryland-based private life sciences tools company developing proprietary electrochemiluminescence-based multiplex immunoassay instruments, assays, and consumables for pharmaceutical, biotech, academic, and clinical research customers across 15+ countries.

Ownership category

akta.pro rank

Product category

Immunoassay Instruments and Reagents

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical Equipment and Supplies Manufacturing (3391)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

akta.pro secondary industries

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

Keywords

• Multiplex immunoassays
• Electrochemiluminescence detection
• Biomarker measurement platforms
• Immunoassay instrumentation
• Life sciences reagents

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Instrument Sales: Sale of proprietary instruments including MESO SECTOR S 600MM, MESO QuickPlex SQ 120MM, and MESO QuickPlex Q 60MM for reading MSD assays.
2. Assay Kits and Consumables: Sale of assay kits including V-PLEX, U-PLEX, S-PLEX, R-PLEX, and T-PLEX product lines. Recurring revenue from consumables required to run assays.
3. Reagents and Plates: Sale of immunoassay plates, reagents, diluents, and buffers as consumable supplies for MSD instrument systems.
4. Custom Services: Fee-for-service offerings including custom assay development, biomarker screening services, custom conjugation, and prototype printing.
5. S-PLEX Services: Specialized high-sensitivity testing services using S-PLEX platform including Tau pT217 and pT181 sample testing services.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Meso Scale Diagnostics develops, manufactures, and sells electrochemiluminescence-based multiplex immunoassay instruments (MESO SECTOR S 600MM, MESO QuickPlex SQ 120MM, MESO QuickPlex Q 60MM), proprietary assay kit lines (S-PLEX, V-PLEX, U-PLEX, R-PLEX, T-PLEX, COVID-19), specialized immunoassay plates, reagents and buffers, and analysis software (DISCOVERY WORKBENCH / Methodical Mind). The company also offers fee-for-service custom assay development, biomarker screening, S-PLEX contract testing, custom conjugation, and prototype printing for pharmaceutical, academic, clinical, and government research customers.

Product overview

Meso Scale Discovery (MSD) offers an integrated platform for biomarker measurement comprising proprietary electrochemiluminescence-based instruments, multiplex assay kits, and supporting services. The core instrument portfolio includes three multiplex immunoassay readers: MESO SECTOR S 600MM (high-throughput), MESO QuickPlex SQ 120MM, and MESO QuickPlex Q 60MM (newest compact model). These instruments run multiple assay platforms: S-PLEX (ultrasensitive assays offering up to 100x higher sensitivity than ELISA for neurological markers like neurofilament L, GFAP, and tau), V-PLEX (validated reproducible multiplex assays for cytokines, chemokines, and disease biomarkers), U-PLEX (customizable configurations from 300+ analytes), R-PLEX (flexible matched antibody sets), and T-PLEX formats. Data analysis is handled through DISCOVERY WORKBENCH and Methodical Mind software. Services include S-PLEX sample testing, custom assay development, biomarker screening, custom conjugation, prototype printing, and a CRO Partner Guide. The portfolio is supported by specialized consumables including immunoassay plates, ELISA conversion packs, and a comprehensive reagent portfolio. The company has received its first FDA clearance for an IVD assay, marking entry into clinical diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• S-PLEX: Ultrasensitive assay platform for high-sensitivity biomarker detection.
• V-PLEX
• U-PLEX
• R-PLEX
• T-PLEX
• MULTI-ARRAY
• Methodical Mind

Products and services

• MESO SECTOR S 600MM High-throughput multiplex immunoassay instrument that reads MSD's electrochemiluminescence-based assays for biomarker measurement in research settings.
• MESO QuickPlex SQ 120MM Multiplex immunoassay instrument delivering high sensitivity and wide dynamic range for biomarker detection in research applications.
• MESO QuickPlex Q 60MM Compact multiplex immunoassay instrument offering high-performance biomarker measurement for research settings with limited bench space.
• DISCOVERY WORKBENCH / Methodical Mind analysis software Data analysis software for MSD instruments, providing instrument control, plate reading, and assay result analysis (version 4.0).
• S-PLEX Assays Ultrasensitive immunoassay platform delivering up to 100x higher sensitivity than conventional ELISA, supporting detection of low-abundance biomarkers including neurofilament L, GFAP, and tau proteins.
• V-PLEX Assays Validated multiplex biomarker immunoassays providing reproducible results across cytokines, chemokines, neurodegeneration, and cardiovascular biomarkers, with a V-PLEX Plus variant for enhanced performance.
• U-PLEX Assays Customizable multiplex immunoassay platform enabling researchers to build personalized biomarker panels from an extensive library of analytes for flexible research applications.
• R-PLEX Assays Matched antibody sets providing flexibility for custom assay development with validated antibody pairs across various research applications.
• T-PLEX Assay Kits Multiplex assay kits supporting simultaneous measurement of multiple analytes from single research samples.
• COVID-19 Assay Kits Assay kits for detection of SARS-CoV-2 antibodies, including variant-specific tests and assays used in vaccine clinical trials, covering Spike protein and nucleocapsid targets across multiple variants.
• S-PLEX Services Contract testing services using the S-PLEX ultrasensitive platform for biomarker analysis on customer samples, including Tau pT217 and pT181 sample testing.
• Assay Development Service Custom assay development service leveraging MSD's electrochemiluminescence technology platform to design biomarker detection assays for specific customer requirements.
• Biomarker Screening Services Comprehensive biomarker screening services for research applications using MSD's multiplex assay platforms to identify and quantify biomarkers in customer samples.
• Custom Conjugation Service Custom conjugation service for attaching customer-supplied antibodies or analytes to MSD's electrochemiluminescence platform for personalized assay configurations.
• Prototype Printing Service Rapid prototype printing service for assay development and validation on MSD plates prior to full-scale production.
• CRO Partner Guide Directory of approved contract research organizations that offer MSD-platform assays for outsourced biomarker research projects.
• MSD Training Program Educational training program covering instrument operation, assay protocols, and software usage for MSD customers.
• Immunoassay Plates Specialized electrochemiluminescence plates designed for MSD instruments, available in multiple formats including 96-well and 384-well configurations.
• ELISA Conversion Packs Conversion products that enable laboratories to migrate from traditional single-plex ELISA workflows to MSD's electrochemiluminescence-based multiplex assays.
• Reagents, Diluents and Buffers Complete portfolio of reagents, diluents, and buffers required for running MSD assays, including Read Buffers, Wash Buffers, and assay-specific formulations.

Quantifiable outcome

• Enables measurement of multiple biomarkers simultaneously from a single sample

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• CORE (Center for Orangutan Research)minorStrategic or Co-development Partner · 26 February 2019Collaboration advancing Meso Scale Discovery technology for tear film biomarker identification research.
• BioAgilytixminorChannel Partner/ Reseller/ Distributor · 5 March 2014First CRO to validate MSD's V-PLEX Human Cytokine 30-Plex Assay. BioAgilytix provides contract research services using MSD technology.
• Bristol-Myers SquibbcoreStrategic or Co-development Partner · 28 March 2011Agreement to develop diagnostic assays for Alzheimer's disease. This strategic partnership leveraged MSD's electrochemiluminescence technology platform for companion diagnostic development in neuroscience.
• Global DistributorscoreChannel Partner/ Reseller/ DistributorComprehensive global distribution network with regional distributors serving customers throughout North America, Europe, and Asia.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• PerkinElmer: PerkinElmer provides a broad life sciences tools portfolio including immunoassays, reagents, and detection instruments that overlap with MSD's research and clinical biomarker workflow offerings.
• Roche Diagnostics: Roche Diagnostics operates Elecsys and other immunoassay platforms in clinical diagnostics and life science research, competing with MSD's IVD ambitions and broader biomarker measurement workflows.
• Abbott Laboratories: Abbott's ARCHITECT and Alinity immunoassay platforms compete with MSD in clinical diagnostics, and Abbott's broader diagnostics franchise rivals MSD's ambitions for IVD biomarker products.
• Danaher (Beckman Coulter Life Sciences): Danaher's Beckman Coulter and Cytiva franchises offer flow cytometry, immunoassay reagents, and life sciences research tools that partially overlap with MSD's multiplex biomarker detection portfolio.
• Siemens Healthineers: Siemens Healthineers' ADVIA Centaur and Atellica immunoassay systems compete with MSD in clinical diagnostics, while its broader life sciences portfolio overlaps with MSD's research-use offerings.
• Revvity (formerly PerkinElmer Life Sciences): Revvity provides multiplex immunoassay platforms (e.g., LEGENDplex-like reagents) and research reagents serving the same pharma and academic biomarker research customer base as MSD.

Direct peers

• Quanterix: Quanterix's Simoa single-molecule array platform competes head-to-head with MSD's S-PLEX in ultrasensitive biomarker detection, particularly in neurology (neurofilament L, tau, GFAP) and immuno-oncology applications.
• Olink (Thermo Fisher Scientific): Olink's Proximity Extension Assay (PEA) technology is an emerging multiplex proteomics platform competing with MSD's U-PLEX and V-PLEX for high-content biomarker discovery in pharma and academic research.
• Bio-Rad Laboratories: Bio-Rad's Bio-Plex multiplex immunoassay system directly competes with MSD's V-PLEX and QuickPlex readers for cytokine, chemokine, and biomarker profiling workflows in research and clinical labs.
• Luminex (DiaSorin): Luminex's xMAP bead-based multiplex immunoassay system is the closest historical competitor to MSD's V-PLEX platform, serving pharma, clinical research, and academic labs with similar multiplexing use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

• Xlinkedin.com/company/meso-scale-diagnostics
• LinkedInlinkedin.com/company/meso-scale-diagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meso Scale Diagnostics